Abstract: Methods of treating or reducing the risk of obesity and/or obesite-related disorders, e.g., metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes, using C20orf27 proteins or nucleic acids.

Abstract: The present invention provides compositions and methods of use thereof for treating or ameliorating multiple sclerosis (MS) by administering a depot formulation comprising 40 mg glatiramer acetate intramuscularly to the MS patient.

Abstract: The present invention relates to natural or natural-like analogues of insect pyrokinin neuropeptides and AKH neuropeptides, and combinations thereof, having activity against insects, for example hemipteran, dipteran, lepidopteran, blattodean and/or coleopteran insects, such as aphids, moths and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

Abstract: The present invention relates to a compound for stabilizing enzymes, the use of said compound for stabilizing an enzyme, a composition comprising said compound, a method of preparing the composition comprising said compound, a detergent composition comprising said compound and a method of preparing said compound.

Abstract: The present invention discloses an anti-aging sturgeon roe tetrapeptide, having a peptide sequence of NLPL (SEQ ID NO: 9). The present invention further discloses a preparation method of the anti-aging sturgeon roe tetrapeptide, specifically comprising the following steps: (1) adding deionized water to sturgeon roes and homogenizing to obtain a sturgeon roe homogenate; (2) adjusting a pH value of the sturgeon roe homogenate, adding alkaline protease, performing enzymolysis and enzyme inactivation, and cooling to obtain sturgeon roe enzymatic hydrolysate; and (3) centrifuging the sturgeon roe enzymatic hydrolysate, taking a supernatant to obtain anti-aging sturgeon roe tetrapeptide, and storing for later use. The sturgeon roe peptide prepared by the present invention can improve the levels of oxidative stress and skin related factors (type I collagen and hyaluronic acid) by adjusting a cell proliferation state, so as to realize the protective effect on skin cells at a cellular level.

Abstract: The present invention relates to novel small molecules Formula I and pharmaceutically acceptable salts thereof as well as the preparation and the use thereof to inhibit FGF13-1b.

Abstract: Modified integrin polypeptides are provided. Methods of identifying binding agents that bind to a modified integrin polypeptide are also provided.

Abstract: The present disclosure provides tumor-specific cleavable linkers and their use in drugs and prodrugs for delivering therapeutics to a tumor cell environment. The present disclosure also provides cleavage products of said drugs and prodrugs, and methods related to the use of the same.

Abstract: The present invention relates to natural or natural-like analogues of insect pyrokinin neuropeptide [Hy]-SPPYSPPFSPRL-[NH2] (SEQ ID NO:2) having activity against insects, for example hemipteran, dipteran, lepidopteran and/or coleopteran insects, such as aphids, moths and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

Abstract: Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for targeting glucagon-like peptide 1 receptor (GLP1R). In certain embodiments, provided are peptidomimetic payloads and linker-payloads and methods of making same. More specifically, GLP1 peptidomimetics, antibody-drug conjugates, and compositions which comprise anti-GLP1R antibodies and GLP1 peptidomimetic payloads and methods of treating GLP1R-associated conditions are provided.

Abstract: Antimicrobial peptides (AMPs), small compounds that often exhibit broad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog (Rana (Lithobates) catesbeiana) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.

Abstract: This disclosure provides non-naturally occurring truncated elastin molecules. The non-naturally occurring truncated elastin may improve the firmness, elasticity, brightness, hydration, tactile texture, and/or visual texture of skin. The non-naturally occurring truncated elastin may reduce degradation of the extracellular matrix.

Abstract: The present invention relates to peptides, in particular cell-penetrating peptides, and to conjugates of such cell-penetrating peptides with a therapeutic molecule. The present invention further relates to use of such peptides or conjugates in methods of treatment or as a medicament, especially in the treatment of genetic disorders and in particular muscular dystrophies such as Duchenne muscular dystrophy.

Abstract: The invention provides a peptide for complexing zinc ion, complex thereof and use therefor. The amino acid composition and sequence of the peptide for complexing zinc ion are Lys-Tyr-Lys-Arg-Gln-Arg-Trp (SEQ ID NO: 1). The peptide for complexing is derived from soybean or peanut, is an inherent component of foods, and has a super strong complexing effect with zinc ions.

Abstract: Disclosed is a human hepatocyte growth factor (hHGF) mutant. Also disclosed are a nucleic acid molecule encoding the mutant, a carrier containing the nucleic acid molecule, and a host cell containing the nucleic acid molecule or the carrier. At the same time disclosed are a pharmaceutical composition comprising the hHGF mutant or the nucleic acid molecule encoding the mutant, and the uses of the hHGF mutant or the nucleic acid molecule encoding the mutant.

Abstract: A polypeptide, a photoresist composition including the polypeptide, and a method of forming patterns by using the photoresist composition.

Abstract: A method of inhibiting myostatin signaling via a myostatin splice variant-derived protein is provided. The protein and an expression system thereof are applicable to therapy for diseases in which myostatin is involved.

Abstract: The invention relates to a fusion protein comprising a main protein and one or more extension peptides, wherein the amino acid sequence of the main protein is identical or similar to the amino acid sequence of a mammalian protein or a fragment thereof, and said extension peptide comprises a cluster of O-glycosylated amino acids. The extension peptide is identical to a non-repeated sequence of the mammalian protein and/or identical or similar to SEQ ID NO: 1. The main protein is preferably VWF. The fusion protein has an increased half life as compared to the main protein and may be used to increase the half-life of a binding partner, e.g. FVIII. The invention further relates to the complex formed by the fusion protein, a polynucleotide encoding the fusion protein as well as a vector and host cell comprising the polynucleotide.

Abstract: Described herein are methods and compositions for the treatment of cancer and cancer metastasis. Methods for the reduction or prevention of cancer metastasis are also described. In particular, the present invention discloses the use of the IL-1? pro-piece peptide in the treatment cancer and cancer metastasis.

Abstract: In an embodiment, the present disclosure pertains to a method of treating or preventing C. difficile infections. In some embodiments, the method includes administering an antitoxin to a subject in need thereof. In some embodiments, the antitoxin includes a designed ankyrin repeat protein (DARPin). In an additional embodiments, the present disclosure pertains to a composition including an antitoxin for treating or preventing C. difficile infections. In some embodiments, the anti-toxin includes a DARPin. In some embodiments, the anti-toxin is a monomeric or dimeric DARPin for the neutralization of Clostridium difficile toxin B (TcdB).